US hospitals use 2.5 million IV bags daily. The flexible PVC tubing delivering those fluids can contain up to 80% plasticizer by weight. For decades, that plasticizer was DEHP (di-2-ethylhexyl phthalate). The regulatory landscape is now shifting toward stricter requirements, and procurement managers face a fragmented maze of FDA guidance, EU MDR mandates, ISO 10993 testing protocols, and a default selection (“just use DOTP”) that breaks down the moment the application involves lipid-contact fluids or multi-material tubing assemblies.
This guide covers what qualifies a plasticizer as medical grade, how US and EU requirements compare, what testing standards actually require, and a three-filter process for matching a plasticizer to a specific medical application — not a generic ranking.
What Makes a Plasticizer Medical Grade?
Medical-grade plasticizers must meet three requirements that industrial plasticizers often do not: biocompatibility, controlled migration, and regulatory compliance documentation.
The EU Medical Device Regulation (MDR 2017/745) sets the clearest threshold. Substances classified as CMR 1A or 1B (carcinogenic, mutagenic, or reproductive toxic) cannot exceed 0.1% by mass in devices contacting patients. DEHP falls into this category. For devices requiring higher concentrations, manufacturers must provide justification based on clinical benefit versus risk.
The FDA takes a risk-based approach rather than setting hard thresholds. Two factors determine risk: aggregate patient exposure and sensitivity of the exposed population. FDA guidance establishes Tolerable Intake (TI) values for DEHP at 0.60 mg/kg/day for parenteral exposure and 0.04 mg/kg/day for oral exposure. Devices must demonstrate patient exposure stays below these limits.
The practical difference: EU MDR restricts the material composition, while FDA focuses on patient exposure. A device might comply with one framework but not the other. Non-phthalate plasticizers simplify compliance by avoiding CMR classification entirely.
Regulatory Frameworks: FDA vs EU MDR
FDA Approach
FDA does not ban DEHP in medical devices. Instead, guidance recommends labeling devices containing DEHP when they contact patients in high-risk categories: male neonates, pregnant women, and perinatal females. The agency’s 2002 guidance remains the primary reference, though California’s Toxic-Free Medical Devices Act (effective 2030) will impose stricter state-level requirements.
FDA relies on device manufacturers to evaluate biocompatibility under 21 CFR Part 820 quality system requirements. The agency endorses ISO 10993-1 as the framework for biological evaluation. Manufacturers bear responsibility for demonstrating their specific device meets safety thresholds.
EU MDR Requirements
EU MDR 2017/745 takes a precautionary approach. Article 10(4) requires that CMR 1A/1B substances above 0.1% concentration receive justification in technical documentation. The SCHEER (Scientific Committee on Health, Environmental and Emerging Risks) updated guidelines in June 2024 provide current risk assessment methodology.
The July 2030 deadline requires full MDR compliance for all medical devices. Devices grandfathered under previous directives must transition or exit the market.
Where They Converge
Both frameworks are converging toward similar outcomes through different mechanisms. California 2030 and EU MDR 2030 create parallel phase-out pressures. The market trend across regions is clear: DEHP-free formulations are becoming the default specification for new device development.
Specifying to the stricter EU 0.1% threshold typically satisfies FDA requirements as well, simplifying global supply chains.
Testing Standards Explained
ISO 10993 Series
ISO 10993 is the international standard for biological evaluation of medical devices. Part 1 provides the framework; subsequent parts address specific tests. For plasticizers, three parts matter most:
ISO 10993-5 covers cytotoxicity testing. Extracts from materials contact cell cultures; cell death indicates toxicity. This screens for acute cellular harm.
ISO 10993-17 establishes allowable limits for leachable substances. It defines how to calculate Tolerable Intake (TI) or Tolerable Exposure (TE) values based on toxicological data.
ISO 10993-18 addresses chemical characterization. Chemical characterization is the first step in biological evaluation. This standard was added to EU MDR harmonized standards in March 2024, making it effectively mandatory for EU market access.
USP Class VI
USP Class VI is the most stringent United States Pharmacopeia classification for plastics. The protocol requires three tests:
- Systemic injection test: Material extracts injected into animals, monitored for 72 hours for systemic reactions
- Intracutaneous test: Checks for local skin reactions at injection sites
- Implantation test: Materials implanted in tissue, response observed for 120+ hours
Extracts are processed at three temperature/time conditions (122°F/72h, 158°F/24h, 250°F/1h) to simulate various use scenarios.
USP updates take effect in stages: USP <665> on May 1, 2026, with USP <88> and <87> updates following on December 1, 2026. These changes align USP more closely with ISO 10993, reducing duplicate testing requirements.
Extractables vs Leachables
Extractables testing uses exaggerated laboratory conditions to identify everything that could migrate from a material. Leachables testing uses conditions simulating actual use to identify what does migrate.
A plasticizer might show high extractables under aggressive solvents but minimal leachables under realistic blood or saline contact. Both data points matter: extractables for safety assessment, leachables for exposure calculations.
Migration Rates by Plasticizer
Migration rates vary widely between plasticizer types. Using DEHP as the baseline:
| Plasticizer | Migration vs DEHP | Best For |
|---|---|---|
| DINCH | 8× lower | Blood storage, transfusion |
| DEHT (DOTP) | 18× lower | General medical, cost-sensitive |
| TOTM | 100–350× lower | Drug infusion, chemotherapy |
A cardiac surgery study demonstrated the practical impact: TOTM migration in heart-lung machine tubing measured 350× lower than DEHP, with no cytotoxicity detected in TOTM metabolites. For extended blood contact during surgery, this difference matters.
Why DOTP Is Not the Universal Answer
Most selection guides rank DOTP first because it works for the largest number of applications at the lowest cost. That ranking is accurate in aggregate and misleading in specifics.
DOTP migration from PVC infusion devices reaches 0.40–0.70% of initial plasticizer content within 24 hours at clinical flow rates. TOTM, by comparison, releases only 0.02–0.14% under identical conditions — a 3- to 35-fold difference depending on the device configuration.
The molecular structure explains why. DOTP’s terephthalate backbone gives it excellent compatibility with PVC and a high LD50 (5,000 mg/kg oral, rats), but its molecular weight and linear geometry allow faster diffusion through the polymer matrix. Trimellitates like TOTM have a branched, higher-molecular-weight structure that physically resists migration. The compatibility between plasticizer and polymer is good in both cases — the difference is in how aggressively the plasticizer leaves the polymer when a fluid provides a thermodynamic driving force.
For simple saline-contact tubing sterilized with EtO, this distinction stays academic. Once your tubing carries total parenteral nutrition, blood products, or lipid emulsions — or once autoclave temperatures accelerate molecular mobility — the migration gap becomes a disqualifying factor.
The Three-Filter Selection Process
Instead of ranking plasticizers by cost or general biocompatibility, run every candidate through three filters in sequence. The candidates that survive all three are your shortlist.
Filter 1: Sterilization Method
Sterilization compatibility eliminates candidates before any other variable.
- Ethylene oxide (EtO) is the gentlest. Most alternatives survive without measurable property change.
- Gamma and e-beam irradiation demand UV stabilizer packages and can yellow certain formulations. Confirm your candidate has gamma-specific stability data — generic claims are not sufficient.
- Autoclave (steam at 121 °C or higher) is the harshest filter. High temperature accelerates plasticizer volatilization and migration simultaneously. ATBC, with its lower molecular weight, is particularly vulnerable. TOTM and polymeric plasticizers handle autoclave cycles better due to their higher thermal stability.
If your sterilization method is autoclave, eliminate ATBC and scrutinize DOTP closely.
Filter 2: Fluid Contact Type
What fluid contacts your tubing changes the answer more than any other variable.
Saline and aqueous solutions. In a 28-day wet storage study on ECMO circuitry, PVC tubing in sodium chloride solution released 0.013 mg/mL of DEHP-type plasticizer — the lowest migration of any fluid tested. TOTM-plasticized tubing in the same saline released roughly 65% of that. For aqueous-contact tubing (saline drip lines, irrigation tubing, drainage sets), DOTP is a defensible choice. Migration stays within regulatory limits, the cost premium is manageable (3–45 cents per pound over DEHP), and processing adjustments are minimal.
Lipid-containing and protein solutions. Albumin-containing priming fluid pulled 0.079 mg/mL of plasticizer from PVC tubing in the same ECMO wet storage study — six times higher than saline. Lipid emulsions act as solvents for ester-based plasticizers, creating a much stronger thermodynamic driving force for migration. This is where DOTP’s position collapses. A 3- to 35-fold migration disadvantage versus TOTM in aqueous systems widens further when lipids enter the picture. For TPN lines, blood product tubing, and any application where the fluid has significant lipid or protein content, TOTM or polymeric plasticizers are the only responsible choices.
Filter 3: Regulatory Market and Multi-Material Compatibility
Your target regulatory market dictates documentation requirements. FDA clearance, EU MDR compliance under ISO 10993, and Asia-Pacific markets each carry different plasticizer selection expectations for biocompatibility testing depth and extractable limits.
Multi-material compatibility is the final screen most formulators miss. Medical devices rarely use PVC tubing in isolation — connectors, housings, and valves are typically ABS, acrylic, polycarbonate, or polystyrene. A Teknor Apex migration study rated DOTP as usable for contact only with ABS among four common non-PVC medical device materials. Acrylic, polycarbonate, and polystyrene all showed unacceptable softening or cracking from DOTP migration. TOTM and polymeric plasticizers were the only two rated acceptable for all four.
If your tubing assembly includes any rigid non-PVC component beyond ABS, DOTP fails this filter regardless of its fluid contact or sterilization performance. For multi-material assemblies, start your DOTP evaluation with material compatibility testing before anything else — or default directly to TOTM.
Application-Specific Selection Summary
After running the three filters, the practical matches are:
| Application | Recommended | Why |
|---|---|---|
| Blood storage and transfusion | DINCH | Preserves red blood cell quality. Hemolysis at 35 days (0.297–0.342%) stays well below the 0.8% threshold |
| Drug infusion / chemotherapy / lipid TPN | TOTM | Lowest migration, best chemical resistance against lipophilic drugs |
| Cost-sensitive saline/aqueous, EtO-sterilized, single-material | DOTP (DEHT) | Easiest DEHP drop-in; cost premium typically below 10% of compound price |
| Multi-material assembly (PC, acrylic, PS connectors) | TOTM or polymeric | Only candidates rated acceptable across all four common rigid plastics |
| Autoclaved, lipid-contact, or extended-residence | TOTM | Survives autoclave thermal load; resists extraction under lipid driving force |
The TOTM Contamination Paradox
TOTM has the best migration profile but carries a hidden compliance issue. The manufacturing process produces phthalic anhydride as a byproduct, resulting in inherent DEHP contamination up to 2,000 ppm. For applications requiring certified DEHP-free status, this contamination may disqualify TOTM despite its superior performance.
DOTP, when produced on dedicated equipment, achieves DEHP levels below 50 ppm. For strict “DEHP-free” certification requirements, DOTP may be the safer specification despite its higher migration rate.
This trade-off is something most suppliers do not discuss. Ask specifically about DEHP contamination levels when specifying TOTM for medical applications.
The Bottom Line
The regulatory landscape is converging around DEHP phase-out. Three deadlines define the transition window:
- May 2026: USP <665> takes effect
- December 2026: USP <88>/<87> updates
- July 2030: EU MDR full compliance; California restrictions effective
Four years is adequate for qualification and supply chain transition, but the window closes faster than most procurement cycles anticipate.
Plasticizer selection should match application risk, not pick from a generic ranking. Blood contact favors DINCH. Extended drug infusion and any lipid-contact application favors TOTM. Cost-sensitive, single-material, EtO-sterilized aqueous tubing remains DOTP’s domain — but that is the boundary, not the default. Requesting migration test data, sterilization compatibility data, multi-material compatibility ratings, and DEHP contamination certificates from suppliers provides concrete evaluation criteria beyond marketing claims.
The shift away from DEHP is no longer a question of whether, only when and how smoothly. Starting qualification work now prevents supply disruptions when deadlines arrive.